LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Veracyte Inc

Veracyte Inc

Chiusa

SettoreSettore sanitario

44.94 -0.64

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

43.38

Massimo

45.53

Metriche Chiave
By Trading Economics
Entrata	-20M 29M
Vendite	-1.6M 139M
P/E Media del settore	38.426 49.701
EPS	0.52
Margine di Profitto	20.642
Dipendenti	755
EBITDA	-17M 29M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+0.2% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	642M 3.3B
Apertura precedente	45.58
Chiusura precedente	44.94

Notizie sul Sentiment di mercato

By Acuity

13%

87%

17 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

30.5 / 31.38 Supporto e resistenza

Veracyte Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mag 2026, 22:52 UTC

I principali Market Mover

Osisko Shares Fall on Planned Convertible Notes Offering

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mag 2026, 23:44 UTC

Utili

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mag 2026, 23:35 UTC

Discorsi di Mercato

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mag 2026, 23:30 UTC

Discorsi di Mercato

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mag 2026, 23:15 UTC

Discorsi di Mercato

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mag 2026, 23:14 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mag 2026, 23:02 UTC

Discorsi di Mercato

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 22:27 UTC

Discorsi di Mercato

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mag 2026, 22:14 UTC

Discorsi di Mercato

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mag 2026, 22:10 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mag 2026, 22:00 UTC

Utili

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mag 2026, 21:38 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mag 2026, 21:27 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mag 2026, 21:20 UTC

Utili

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mag 2026, 21:19 UTC

Utili

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mag 2026, 21:18 UTC

Utili

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mag 2026, 21:17 UTC

Utili

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mag 2026, 21:16 UTC

Utili

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Veracyte Inc Previsione

Obiettivo di Prezzo

By TipRanks

0.2% in crescita

Previsioni per 12 mesi

Media 45.28 USD 0.2%

Alto 52 USD

Basso 39.7 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Veracyte Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Veracyte Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.5 / 31.38Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

17 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.